Investigational anticancer compound could promote myelin repair in multiple sclerosis

Written by Alice Weatherston, Future Science Group

An experimental cancer drug, termed GANT61, which was originally identified as a potential therapy for brain and basal cell cancers, has been highlighted as a potential new therapeutic for multiple sclerosis in a study published this week in Nature. The finding was uncovered by a team of neuroscientists from NYU Langone Medical Center (NY, USA), who administered daily GANT61 to mice with chemically damaged brain myelin for a total of 1 month and noticed symptom improvement with the therapy. Analysis indicated that mice in the treated group had 50% more myelin at the end of the treatment period in comparison...

To view this content, please register now for access

It's completely free